Reuters Pharma USA – Lung-I Cheng
Cell and gene therapies continue to be hot topics in the pharma world this year, and some companies are responding to the new treatment modalities with new business units.
Lung-I Cheng is vice president of cell and gene therapy at Amerisource Bergen, leading the company’s newly-established cell and gene therapy franchise. At Reuters Pharma USA in March, pharmaphorum editor-in-chief Jonah Comstock chatted with Lung-I about what he’d been seeing and hearing at the show about the many challenges and opportunities cell and gene therapies are creating across the pharma ecosystem.
They talk about the tremendous potential these technologies have for patients, but also some of the barriers that need to be overcome, including cost, transportation and logistics, and market access. And they get into the possible impact of value-based care on solving these problems.
Check out the video below, and stay tuned for one more interview from the Reuters USA show floor.